 |
|
Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
Hector S. Izurieta, MD, MPH;
Penina Haber, MPH;
Robert P. Wise, MD, MPH;
John Iskander, MD, MPH;
Douglas Pratt, MD, MPH;
ChrisAnna Mink, MD, MPH;
Soju Chang, MD, MPH;
M. Miles Braun, MD, MPH;
Robert Ball, MD, MPH
JAMA. 2005;294:2720-2725.
Context In June 2003, the US Food and Drug Administration licensed a trivalent live, attenuated influenza vaccine (LAIV-T) for intranasal administration to healthy persons 5 to 49 years of age. Although prelicensure testing involved 20 228 vaccinees, clinical trials were not of sufficient size to detect rare adverse events reliably.
Objective To identify adverse events reported following LAIV-T administration after licensure.
Design, Setting, and Participants All adverse events reported to the US Vaccine Adverse Event Reporting System (VAERS) during the 2003-2004 and the 2004-2005 influenza seasons.
Main Outcome Measures Numbers and proportions of reported adverse events and reporting rates of adverse events per 100 000 vaccinees.
Results Approximately 2 500 000 persons received LAIV-T during the first 2 postlicensure seasons. As of August 16, 2005, VAERS received 460 adverse event reports for vaccinations received from August 2003 through July 2005. No fatalities were reported. There were 7 reports of possible anaphylaxis, 2 reports of Guillain-Barré syndrome, 1 report of Bell palsy, and 8 reports of asthma exacerbation among individuals with a prior asthma history. Events in individuals for whom the vaccine was not indicated accounted for 73 reports (16%).
Conclusions Reports to VAERS in the first 2 seasons of LAIV-T use did not identify any unexpected serious risks with this vaccine when used according to approved indications. Like many vaccines and other medical products, LAIV-T may rarely cause anaphylaxis. Secondary transmission of the vaccine virus merits further investigation. Reports of asthma exacerbations in vaccinees with prior asthma history highlight the risks of vaccine use inconsistent with approved labeling.
Author Affiliations: Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Md (Drs Izurieta, Wise, Pratt, Mink, Chang, Braun, and Ball); and National Immunization Office, Office of the Chief Science Officer, Centers for Disease Control and Prevention, Atlanta, Ga (Ms Haber and Dr Iskander).
RELATED ARTICLE
Vaccine Safety—Achieving the Proper Balance
Kathleen M. Neuzil and Marie R. Griffin
JAMA. 2005;294(21):2763-2765.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Trivalent Live Attenuated Intranasal Influenza Vaccine Administered During the 2003 2004 Influenza Type A (H3N2) Outbreak Provided Immediate, Direct, and Indirect Protection in Children
Piedra et al.
Pediatrics 2007;120:e553-e564.
ABSTRACT
| FULL TEXT
Influenza Vaccines
Boyce et al.
NEJM 2007;356:1172-1173.
FULL TEXT
Live Intranasal Influenza Vaccine: Adverse Events Are Minimal
JWatch Pediatrics 2006;2006:8-8.
FULL TEXT
Live Intranasal Influenza Vaccine: Adverse Events Are Minimal
JWatch Infect. Diseases 2006;2006:2-2.
FULL TEXT
What's new in the other general journals
Tonks
BMJ 2005;331:1427-1427.
FULL TEXT
Vaccine Safety--Achieving the Proper Balance
Neuzil and Griffin
JAMA 2005;294:2763-2765.
FULL TEXT
|
